PolyPid Future Growth
Future criteria checks 0/6
PolyPid's earnings are forecast to decline at 1.7% per annum. EPS is expected to grow by 106.9% per annum.
Key information
-1.7%
Earnings growth rate
106.9%
EPS growth rate
| Pharmaceuticals earnings growth | 23.0% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 15 Feb 2024 |
Recent future growth updates
Recent updates
PolyPid set to cut 20% jobs
Oct 20PolyPid's surgical site infections treatment eligible for marketing nod submission in EU
Sep 28PolyPid sheds 75% as lead candidate fails in Phase 3 trial for post-surgical infections
Sep 02PolyPid GAAP EPS of -$1.23 misses by $0.60
Aug 10PolyPid to get $2.6M upfront under license deal with Advanz for D-PLEX in Europe
Aug 03PolyPid: Strong Pipeline, Close Catalysts
Apr 19Will PolyPid (NASDAQ:PYPD) Spend Its Cash Wisely?
Mar 18
Here's Why We're Watching PolyPid's (NASDAQ:PYPD) Cash Burn Situation
Nov 08We Think PolyPid (NASDAQ:PYPD) Can Afford To Drive Business Growth
Jul 15Here's Why We're Not Too Worried About PolyPid's (NASDAQ:PYPD) Cash Burn Situation
Mar 09PolyPid's oncoplex cancer program shows encouraging action in animal study
Dec 22PolyPid launches second late-stage trial with D-PLEX100 in surgical infections
Dec 16PolyPid pops 24% after D-PLEX100 nabs accelerated review in U.S. for preventing surgical infections
Nov 24Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | N/A | -24 | N/A | N/A | 1 |
| 12/31/2024 | N/A | -26 | N/A | N/A | 2 |
| 12/31/2023 | N/A | -24 | -17 | -17 | N/A |
| 9/30/2023 | N/A | -24 | N/A | N/A | N/A |
| 6/30/2023 | N/A | -28 | -23 | -22 | N/A |
| 3/31/2023 | N/A | -34 | N/A | N/A | N/A |
| 12/31/2022 | N/A | -40 | -36 | -34 | N/A |
| 9/30/2022 | N/A | -46 | N/A | N/A | N/A |
| 6/30/2022 | N/A | -47 | -42 | -39 | N/A |
| 3/31/2022 | N/A | -46 | N/A | N/A | N/A |
| 12/31/2021 | N/A | -43 | -35 | -32 | N/A |
| 9/30/2021 | N/A | -41 | N/A | N/A | N/A |
| 6/30/2021 | N/A | -37 | -29 | -28 | N/A |
| 3/31/2021 | N/A | -46 | N/A | N/A | N/A |
| 12/31/2020 | N/A | -43 | -23 | -22 | N/A |
| 9/30/2020 | N/A | -42 | N/A | N/A | N/A |
| 6/30/2020 | N/A | -37 | N/A | N/A | N/A |
| 3/31/2020 | N/A | -19 | -18 | -17 | N/A |
| 12/31/2019 | N/A | -13 | -18 | -17 | N/A |
| 12/31/2018 | N/A | 0 | -20 | -17 | N/A |
| 12/31/2017 | N/A | -59 | -14 | -12 | N/A |
| 9/30/2017 | N/A | -20 | N/A | -11 | N/A |
| 12/31/2016 | N/A | -14 | N/A | -10 | N/A |
| 12/31/2015 | N/A | -11 | N/A | -7 | N/A |
| 6/30/2014 | N/A | -6 | N/A | -3 | N/A |
| 3/31/2014 | N/A | -5 | N/A | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PYPD is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PYPD is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PYPD is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if PYPD's revenue is forecast to grow faster than the US market.
High Growth Revenue: PYPD is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PYPD's Return on Equity is forecast to be high in 3 years time